Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder

Objectives: To evaluate the short-term efficacy and safety of desvenlafaxine (25–50 mg/d) compared with placebo in children and adolescents with major depressive disorder (MDD). Methods: Outpatient children (7–11 years) and adolescents (12–17 years) who met DSM-IV-TR criteria for MDD and had screeni...

Descripción completa

Detalles Bibliográficos
Autores principales: Weihs, Karen L., Murphy, William, Abbas, Richat, Chiles, Deborah, England, Richard D., Ramaker, Sara, Wajsbrot, Dalia B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771543/
https://www.ncbi.nlm.nih.gov/pubmed/29189044
http://dx.doi.org/10.1089/cap.2017.0100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771543/
https://www.ncbi.nlm.nih.gov/pubmed/29189044
http://dx.doi.org/10.1089/cap.2017.0100

Ejemplares similares